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CYTOKINES IN THE KIDNEY
TGF-J3 in kidney fibrosis: A target for gene therapy
WAYNE A. BORDER and NANCY A. NOBLE
Fibrosis is a pathological process that results from some form of
injury and can occur in any organ. When fibrosis develops it
typically causes tissue dysfunction and organ failure. The biolog-
ical cause of fibrosis is the accumulation of excessive amounts of
extracellular matrix within a tissue. Fibrosis within glomeruli
(glomerulosclerosis) and between tubules (tubulointerstitial fibro-
sis) causes the progressive loss of renal function that leads to
end-stage renal disease in humans with diabetes, glomerulone-
phritis or hypertension. It is now widely believed that fibrosis
represents an excess of the normal repair process that follows
tissue injury and, accordingly, fibrosis has been termed the "dark
side" of tissue repair [1]. The idea that normal tissue repair and
fibrogenesis are closely related is based on the overwhelming
evidence that both involve similar biological processes that are
regulated by the same group of molecules [2]. A prime example of
this is the role of transforming growth factor-n (TGF-p).
TGF-13 is a cytokine or signaling molecule whose potent
fibrogenic properties are derived from its multiple actions in
tissue repair [3, 4]. TGF-f3 is unique in its ability to stimulate
strongly the deposition of extracellular matrix by four separate,
simultaneous effects, as depicted in Figure 1. TGF-p acts directly
to stimulate the synthesis of most matrix molecules including
fibronectin, collagens and proteoglycans. At the same time,
TGF-f3 blocks the degradation of matrix by inhibiting the secre-
tion of proteases and inducing the production of protease inhib-
itors. TGF-f3 also modulates the expression of integrin matrix
receptors on cells in a manner that facilitates cell-matrix adhesion
and matrix deposition. Finally, TGF-/3 autoinduces its own pro-
duction, which greatly amplifies its biological actions. These four
fibrogenic effects of TGF-13 have been demonstrated indepen-
dently in several types of cultured cells. However, in a model of
acute glomerulonephritis, we have shown these TGF-13 effects as
the cause of the rapid deposition of matrix in the injured
glomeruli.
TGF-13 in acute glomerulonephritis
The model of acute mesangial proliferative glomerulonephritis
in the rat produced by a single injection of anti-thymocyte serum
(ATS) is ideal to study the molecular events in fibrogenesis [5].
Mesangial cells, but not other glomerular cells, have a Thy-i-like
antigen on their surface [6]. Injection of ATS causes a dose- and
complement-dependent lysis of a portion of the mesangial cell
population [7]. The injured mesangial cells serve as a stimulus to
initiate the repair process, just as would occur following a knife
wound in the skin. Thus, ATS-induced glomerulonephrits serves a
dual purpose of providing biological insight into the basic mech-
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anisms of normal tissue repair and a new understanding of the
molecular pathogenesis of glomerulonephritis.
TGF-p exists in three isoforms in mammals: TGF-/31, -2 and -3
[8]. In vitro the three isoforms have similar functions, but in vivo
TGF-pl is most strongly implicated in fibrosis [2]. Immediately
upon glomerular injury, TGF-13 is released and activated locally.
TGF-p binds to receptors on glomerular cells and initiates a
signaling cascade that activates a number of genes, including
TGF-/3. Increased local production of TGF-f3 amplifies its biolog-
ical effects.
Stimulated by TGF-p, glomerular cells dramatically increase
the production of fibronectin and types I and III collagen [9, 10].
In addition, TGF-/3 induces the synthesis of a number of novel
matrix molecules that normally are not present and which play
important roles in wound repair. Examples are fibronectin con-
taining extra domain A (fibronectin EDA), tenascin, and plasmin-
ogen activator inhibitor-i (PAl-I). The plasminogen/plasmin pro-
tease system has been shown to play a key role in degradation and
normal turnover of the mesangial matrix [II]. TGF-13's action to
decrease secretion of plasminogen activators and to greatly in-
crease PAl-i production is particularly critical because it com-
pletely blocks plasmin generation by the injured glomeruli [12].
TGF-!3 also stimulates production of tissue inhibitors of metallo-
proteinases (TIMP), which acts to shut down these proteases and
further block matrix degradation. TGF-13 simultaneously induces
increased numbers of integrin receptors to be expressed on the
surface of glomerular cells, for example, the integrins that bind
fibronectin and type I collagen [13]. Integrin receptors bind their
respective matrix ligands, which facilitates assembly of matrix, and
the newly synthesized normal and novel matrix components
rapidly accumulate in the expanding glomerular matrix.
In the ATS model, the simultaneous occurrence of increased
matrix synthesis, decreased matrix degradation and modulation of
integrins underlie the deposition of the pathological matrix and
clearly demonstrate the fibrogenic potency of TGF-p. That these
events are caused by TGF-p has now been demonstrated by
several different lines of investigation. We, as well as others, have
shown that the actions of TGF-13 just described in vivo can be
reproduced in cell culture by addition of exogenous TGF-/3 [9, 10].
Intravascular injection of TGF-/3 into rats or rabbits rapidly
caused glomerulosclerosis [14]. Overexpression of TGF-f3 in
normal, uninjured glomeruli by gene transfection produced gb-
merulosclerosis within days [15]. In other experiments, the TGF-p
gene was coupled to the promoter of the albumin gene and used
to create transgenic mice. In these mice the liver produced large
amounts of TGF-13, which was reflected in greatly increased
plasma levels of TGF-13. Although these mice did show increased
matrix deposition in their livers, they died of renal failure caused
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Fig. 1. The actions of TGF-/3 in causing extracellular matrix deposition. TGF-/3 released at the site of tissue injury induces its own production by cells,
thus greatly amplifying its biologic effects. TGF-13 induces the deposition of extracellular matrix by inducing the production of new matrix proteins,
inhibiting matrix degradation by increasing thesynthesis of protease inhibitors and decreasing the synthesis of proteases and altering the expression of
cell-surface integrins. (Reproduced from [21 with permission).
by a lesion that resembled rapidly progressive crescentic glomer-
ulonephritis with tubulointerstitial fibrosis [161. Finally, fibrosis
has been blocked in vivo by injection of anti-TGF-13 neutralizing
antibodies in a number of animal models including kidney disease
[2].
In normal tissue repair, TGF-f3 does not act alone, but in
concert with other cytokines [17]. Most important are the inter-
actions of TGF-3 with platelet-derived growth factor (PDGF) and
fibroblast growth factor (FGF). The experiments just described
show different roles for each of these cytokines as well as a
complex regulation by TGF-f3 [18]. However, none of these other
cytokines possesses TGF-/3's unique fibrogenic properties [15].
PDGF's most potent effects are on cell proliferation, whereas
FGF strongly induces angiogenesis. It is clear that these three
cytokines, along with others, are important in the normal process
of tissue repair; however, their actions are not redundant and it is
overproduction of TGF-13 that is clearly causal in the pathogenesis
of tissue fibrosis [2].
TGF-j3 in chronic glomerulonephritris: The vicious circle
In the glomerulonephritis model described above, expression of
TGF-/3 peaks about seven days after injection of ATS, and TGF-f3
production subsequently falls to normal levels [5]. As soon as
TGF-/3 levels decrease, matrix synthesis declines, plasmin pro-
tease activity returns, and the number of integrin receptors on
glomerular cells falls. With these events, the buildup of matrix
stops, and over the next several weeks the pathological matrix is
degraded and the glomeruli return to a normal appearance.
Normally, TGF-'s actions are terminated when tissue repair is
completed. Then, what explains the continued overproduction of
TGF-/3 that leads to fibrosis?
We hypothesized that the regulation of gene expression of
TGF-p evolved to respond to a single episode of tissue injury, as
occurs in a dermal wound or in ATS-induced glomerulonephritis.
However, if there were repeated episodes of tissue injury as occurs
in human disease, then a defect in TGF-/3 regulation or continued
autoinduction of TGF-J3, or both, could lead to a "vicious circle"
of TGF-p overproduction and fibrosis, as illustrated in Figure 2.
To test this hypothesis, we created a "two shot" model of
glomerulonephritis in which a second injection of ATS was given
one week later [19].
Comparison of the "two shot" to the "one shot" ATS model
provided evidence that supported our hypothesis. In the "two
shot" model, TGF-/3 expression in the glomeruli persisted, and
after 12 weeks tubulointerstitial expression of TGF-13 was de-
tected in infiltrating myofibroblasts and, subsequently, in tubular
cells. By 18 weeks the persistent production of TGF-13 produced
severe glomerulosclerosis and accompanying tubulointerstitial
fibrosis that closely resembled progressive human disease. In situ
hybridization studies showed that TGF-J3 was widespread and
extensive in the fibrosing kidneys. As well, the expression of
TGF-f3 mRNA and protein colocalized with deposition of the
matrix components and protease inhibitors known to be induced
by TGF-p.
The findings in the "two shot" model supported the idea that
repeated injury results in permanent overproduction of TGF-p,
whereas, following a single episode of injury, the TGF-13 response
is terminated when tissue repair is completed [19]. Results in
other experimental models also support this idea. A classic
example is acute and chronic serum sickness in rabbits. Following
a single injection of bovine serum albumin there is a limited
episode of immune complex deposition that produces an acute,
but reversible, glomerulonephritis. In contrast, repeated injec-
tions of the antigen results in a progressive glomerulonephritis
that leads to fibrosis and renal failure. In humans the same
principle can be seen in the different outcomes between acute
poststreptoccol glomerulonephritis, where immunological injury
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Fig. 2. The vicious circle of TGF-13 overproduction in fibrotic disease. During normal tissue repair, the actions of TGF-13 on fibrogenesis are terminated
when the tissue is healed. In chronic fibrotic disease, repeated tissue injury, a defect in TGF-13 regulation, or both lead to a vicious circle of TGF-f3
overproduction and continuous extracellular matrix deposition. (Reproduced from [21 with permission).
is limited and the disease reversible, and the progressive glomer-
ulonephritis that often results from a chronic disease like lupus,
where injury is prolonged.
Enigma of diabetic nephropathy
Diabetic nephropathy is one of the clearest examples of a
fibrotic disease. It is characterized by the progressive accumula-
tion of extracellular matrix in glomeruli and between tubules until
renal function is destroyed. The question is: why should repeated
elevations of blood sugar cause renal fibrosis? We hypothesized
that glomeruli exposed to the diabetic milieu perceived hypergly-
cemia as injury and turned on TGF-f3 as part of a tissue repair
response. In rats with experimental diabetes, we found increased
expression of the TGF-13 gene within days of the onset of
hyperglycemia [20]. As soon as diabetic glomeruli produced
TGF-f3 there was induction of the genes for matrix proteins.
These proteins, including collagen type 1, biglycan, fibronectin
EDA, tenascin and PAl-i, immediately began to accumulate in
the diabetic glomeruli as part of the genesis of diabetic nephrop-
athy. Note that these are the same matrix components that were
detected in nephritic glomeruli following ATS-induced injury.
Of great clinical interest is the fact that treating diabetic rats
with insulin to control blood sugar levels reduced, but did not
prevent, the increased expression of TGF-3 in glomeruli [201.
Others have shown elevated plasma levels of TGF-13, that is
probably produced by the kidneys, in diabetic rats. Treatment with
insulin decreased the plasma levels of TGF-p and also suppressed
type I collagen production in diabetic kidneys. A high glucose
concentration has been shown to induce TGF-p production by
cultured mesangial cells and renal tubular cells [21]. Taken
together these data suggest that in diabetes, elevated blood
glucose in some way stimulates TGF-p production in the kidney,
and this sets the stage for the progressive fibrosis that underlies
diabetic nephropathy [221.
TGF-j3 in human glomerular disease
We have completed three studies that examined the expression
of TGF-/3 isoforms and two matrix proteins induced by TGF-j3,
fibronectin EDA and PAl-i, in human renal biopsy specimens [20,
23, 241. We always included measurement of these or similar
matrix proteins in our studies, because their production is specif-
ically induced by TGF-13 and they are not present in normal
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Fig. 3. Glomerular (A) and tubulointerstitial (B) staining scores of TGF-/31
•), TGF-/32 (striped bar) and TGF-f33 (LI) in normal control (NC), thin
basement membrane disease (TBMD), minimal change disease (MCD), IgA
nephropathy (IgA), focal and segmental glomerulosclerosis (FSG), crescentic
glomerulonephritis (CresGN), focal proliferative lupus nephritis (FPLN),
diffuse proliferative lupus nephritis (DPLN) and diabetic nephropathy (DN).
(Reproduced from [231 with permission).
tissues, but appear only in injured tissues. Thus, their presence
indicates that TGF-13 detected in the tissue is biologically active. A
spectrum of glomerular diseases was represented in our studies
including focal and segmental glomeruloscierosis, IgA nephropa-
thy, focal and diffuse proliferative lupus nephritis, rapidly progres-
sive glomerulonephritis, diabetic nephropathy and acute and
chronic renal transplant rejection. As controls, we used normal
renal tissue, and biopsy tissue from patients with minimal change
disease or thin basement membrane disease. These diseases were
chosen as controls because they cause urinary abnormalities but
typically do not lead to renal failure or fibrosis.
In the normal and disease controls, we found negative or scant
staining for TGF-pl, -2 and -3, as well as fibronectin EDA and
PAT-i. In contrast, in the progressive glomerular diseases we
found large amounts of the TGF-f3s as well as fibronectin EDA
and PAl-i. TGF-pl was the dominant TGF-/3 isoform found in
the nephritic tissues (Fig. 3). There was a strong positive corre-
lation between the amount of TGF-/31 present in biopsy and the
degree of fibrosis in the underlying glomerular disease. Also, the
more severe the disease the greater the TGF-p staining. For
example, diffuse proliferative lupus nephritis and rapidly progres-
sive glomerulonephritis contained more TGF-/3T than did focal
proliferative lupus nephritis or IgA nephropathy. Substantial
amounts of TGF-f32 and -3 were also present in the diseased
glomeruli (Fig. 3). Whether the effects of TGF-f32 and -3 on
fibrogenesis are additive to that of TGF-f31, or whether these
isoforms are playing other roles is unknown.
In our studies of experimental models of glomerulonephritis
and diabetic nephropathy, we found that TGF-J3 played a com-
mon role in inducing fibrogenesis. We found the same to be true
in human glomerulonephritis and diabetic nephropathy [20, 23].
Human diabetic glomeruli contained large amounts of TGF-p, as
well as fibronectin EDA and PAT-i. However, in the experimental
model we observed the genesis of the fibrotic lesions, whereas in
humans end-stage disease was present. This difference was easily
seen in the different staining patterns for TGF-13. In the rat, the
TGF-/31 staining was mostly within cells, whereas in the human
the staining was primarily in the pathological matrix. Others have
shown that end-stage human sclerotic glomeruli are not metabol-
ically dead, but are actively expressing genes of matrix proteins
likely, as our data suggest, because of the continued overproduc-
tion of TGF-j3 [25].
Both of the matrix markers of TGF-13 activity, fibronectin EDA
and PAT-i, were significantly increased in glomerular diseases
with associated fibrosis [23]. The presence of large amounts of
PAl-i in human disease is of particular interest. As described,
PAT-i blocks the action of plasmin so that matrix is not degraded.
Thus, increased synthesis of matrix components and inhibition of
matrix degradation underlie fibrogenesis in human disease just as
in the experimental models. This suggests a dramatic therapeutic
potential. If TGF-f3 expression were suppressed and the amounts
of PAl-i decreased, the plasmin protease system might be freed to
resume its normal function of degrading matrix. Thus, the pro-
gression of fibrosis would not only be blocked, but existing
pathological matrix might actually regress.
TGF-p as a cause of fibrosis in renal transplant rejection
Chronic transplant rejection is now a leading cause of kidney
failure in the developed world. Furthermore, progressive fibrosis
is the cause of organ failure in the chronically rejecting kidney.
Whether some form of continuing immunological injury is present
is unclear. We and our collaborators investigated renal biopsies
from groups of patients with acute or chronic transplant rejection
[24]. Controls consisted of renal tissue from normal individuals
and from patients with a variety of other kidney diseases. As in
our previous human studies, we examined the biopsies for the
presence of TGF-f31, -2 and -3 and the two matrix protein markers
of TGF-p activity, fibronectin EDA and PAT-i.
In cases of acute rejection, the TGF-/3 isoforms and the matrix
protein markers were significantly expressed in tubulointerstitial
areas of the kidney involved with cellular infiltrates. The glomeruli
were largely normal and showed only background staining or a
slight increase in TGF-J3T. In contrast, cases of chronic rejection
demonstrated large amounts of TGF-/3 throughout the intersti-
tium and in glomeruli. The TGF-/3 was present in cells and in the
fibrotic matrix and was accompanied by significant amounts of
fibronectin EDA and PAl-i.
Analysis of these results suggests that an episode of acute
rejection serves to injure the kidney and induce expression of
TGF-/3. If the lesson learned from the "two shot" model of ATS
glomerulonephritis applies, then repeated episodes of acute re-
jection lead to sustained overproduction of TGF-f3. Furthermore,
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TGF-f3 initially produced in the tubulointerstitium likely autoin-
duces TGF-J3 production in glomeruli. The sustained overproduc-
tion of TGF-13 in the kidney mediates the progressive fibrosis that
is characteristic of chronic transplant rejection.
Another potential factor contributing to failure of the trans-
plant kidney is cyclosporine nephrotoxicity. We and our collabo-
rators hypothesized that interstitial fibrosis, a hallmark of cyclo-
sporine nephrotoxicity, might be caused by the induction of
TGF-f3. To investigate this possibility, a developed animal model
was utilized in which nephrotoxicity is induced by the combination
of cyclosporine administration and salt depletion [26]. In this
model evidence of proximal tubular injury, arteriolopathy and
tubulointerstial fibrosis develop within one month. We found a
significant increase in TGF-13 and PAl-i expression in kidneys of
animals treated with cyclosporine, compared to controls. These
results suggest that TGF-f3 production, induced by cyclosporine,
plays a key role in the nephrotoxicity of this drug.
TGF-3 as a therapeutic target
The evidence that TGF-p is a key mediator of fibrosis in both
experimental and human kidney disease is now overwhelming [2].
This point is further strengthened by the fact that the evidence
comes not only from our laboratory, but also from others using
several diverse lines of investigation, including in vitro and in vivo
studies performed using a variety of different cells, tissues and
models. This body of evidence has recently been reviewed and
provides a clear basis for choosing TGF-f3 as a therapeutic target
for development of an anti-fibrotic agent [2]. Of interest, we have
noted a curious response to such a proposal. It is that, although
TGF-13 is certainly important in fibrogenesis, its multiple functions
and interactions with other cytokines make the system too com-
plex for a therapeutic intervention. Any attempt at blocking
TGF-p would either not work or have serious side effects. This
negative attitude brought to mind an old bit of scientific wisdom
that said that sometimes the best approach is, "don't think, do the
experiment." That is precisely what we did.
Anti-TGF-f3 antibodies
Our initial experiments with neutralizing antibodies were in
vitro. Glomeruli, producing large amounts of matrix proteins,
were isolated from nephritic animals and placed in culture. Next,
neutralizing antibody to TGF-/3 was added to the glomerular
cultures, and within 24 hours we observed that the synthesis of
matrix proteins was dramatically reduced [51. This result encour-
aged us to try the same experiment in vivo.
ATS was used to induce glomerulonephritis in groups of rats
and 24 hours later the nephritic rats were injected with anti-
TGF-/3 antibody, or an unrelated antibody or saline [27]. A single
daily injection of antibody or saline was continued for six days
after which the animals were sacrificed and the kidneys harvested,
Nephritic glomeruli from control rats showed the expected in-
crease in matrix protein production and deposition that is char-
acteristic of this disease model. In striking contrast, nephritic
glomeruli from rats treated with anti-TGF-f3 produced 80% less
matrix proteins. Histologic analysis showed minimal matrix dep-
osition in glomeruli of nephritic rats treated with anti-TGF-
compared to controls. This was the first demonstration of the
therapeutic benefit of blocking the action of TGF-/3 in a disease
model.
Subsequently, other investigators performed a similar experi-
ment in a model of wound repair [28]. They injected anti-TGF-
antibody into the site of a dermal wound in a rat and then
observed the course of the healing wound. The anti-TGF-13-
treated wound healed at a normal rate, but had almost no visible
scar because there was 70% less collagen than in a control wound.
The collagen fibrils in the anti-TGF-f3-treated wound were laid
down in a parallel fashion instead of being in a disorderly array, as
in the control wound, and both wounds had the same tensile
strength. These results supported our hypothesis that TGF-13's
action in fibrosis is closely related to a similar action in normal
tissue repair. Furthermore, our findings, that blocking TGF-p
does not impair normal healing but does prevent the exuberant
cellular production and deposition of excessive amounts of matrix,
were confirmed. Anti-TGF-f3 antibodies have now been used with
similar therapeutic results in models involving kidney, skin, liver,
lung, joint, artery and central nervous system [2].
Decorin
Decorin is the prototypical member of a family of small
proteoglycans that are rich in leucine [29, 30]. Other members are
biglycan, fibromodulin and lumican. Decorin is a naturally occur-
ring molecule that is found in the interstitial extracellular matrix
of most tissues. Decorin and biglycan are structurally similar
except that decorin has one and biglycan two glycosaminoglycan
side chains. The core proteins of decorin and biglycan both bind
TGF-13 and block its biological actions [30]. It is interesting to
remember that the TGF-/3 type III receptor, betaglycan, is also a
proteoglycan. TGF-f3's binding to these proteoglycans is only one
of several known instances in which the actions of cytokines are
regulated by interactions with proteoglycans [29].
Decorin is so named because it binds to or "decorates" type I
collagen fibrils. In so doing, decorin limits the size of fibrils
formed by type I collagen in vitro. Decorin's effect on collagen
fibrillogenesis has now been demonstrated to be important in vivo.
At a recent Gordon Conference, lozzo and coworkers reported
that mice, in whom the decorin gene had been knocked out, are
born with severely fragile skin that easily tears. The structural
basis of the fragile skin was found to be the presence of wide-
spread abnormalities in the size and shape of collagen fibrils.
The production of decorin and biglycan is strongly regulated by
TGF-p but in opposite directions [31]. TGF-p suppresses decorin
gene expression and decreases decorin synthesis but stimulates
production of biglycan. In an early study we reported that decorin
apparently accumulates in the medium of cultured mesangial cells
exposed to TGF-f3 [10]. However, this is not due to increased
production of decorin. TGF-p strongly stimulates biglycan pro-
duction by mesangial cells. Both proteoglycans bind to the same
receptor. In the presence of increased amounts of biglycan,
competition for the receptor slows decorin's internalization and
degradation and decorin appears to increase (unpublished obser-
vations).
The type I collagen gene has a TGF-/3 binding element in its
promoter, as does decorin. TGF-p strongly stimulates the synthe-
sis and deposition of type I collagen into the matrix. Normal
glomeruli do not contain type I collagen and it appears in ATS
nephritic glomeruli on about day four of disease. It is believed that
decorin forms a complex with type I collagen and TGF-f3 that, in
some unknown way, signals the adjacent cells that sufficient matrix
has been produced and to turn off TGF-f3 gene expression [29].
In the acute glomerulonephritis model induced by ATS, we
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Fig. 4. Glomerular expression of TGF-/3 mRNA and TGF-j3 protein siz days
after induction of glomerulonephritis. (A) TGF-j3 mRNA (top panel) from
a rat treated with decorin (lane 1) or CAT (lane 2) gene therapy. Bottom
panels show mRNA levels from GAPDH, a housekeeping gene used as
control. (B) Numbers of TGF-13 positive cells per glomerulus. (Repro-
duced from [39] with permission).
have recently shown that the level of decorin mRNA decreases as
soon as TGF-f3 production is increased [32]. On day 7 of disease,
when TGF-f3 expression is at its peak, decorin protein is nearly
undetectable in the nephritic glomeruli. However, as levels of
TGF-J3 fall, decorin expression is increased and decorin is again
detectable in the glomerular matrix. Thus, at the peak of TGF-'s
fibrogenic actions, there is a relative "deficiency" of decorin in the
tissue. A similar pattern has been observed during fibrogenesis in
the lung [33]. Whether a TGF-p mediated decrease in the tissue
content of decorin is required for TGF-'s fibrogenic actions is
unknown. However, it is clear that administration of exogenous
decorin suppresses TGF-f3 expression and matrix deposition in
injured glomeruli.
In an initial decorin study we compared the effects of intravas-
cular injection of native decorin, derived from bovine bone, and
recombinant human decorin [34]. Control groups were treated
with injections of aggrecan, a proteoglycan that does not bind
TGF-p, bovine serum albumin or saline. A daily injection was
given for the first two, four or six days following administration of
ATS into rats to produce glomerulonephritis. None of the control
molecules or saline affected the disease. Interestingly, two injec-
tions of decorin were also ineffective, possibly because type I
collagen is still absent from nephritic glomeruli at this early time.
Thus, the hypothetical decorin, type I collagen and TGF-j3
complex cannot be generated to signal suppression of TGF-13
production.
Decorin administered for longer than two days ameliorated
manifestations of disease. There was a substantial decrease in the
deposition of fibronectin, fibronectin EDA and tenascin in the
nephritic glomeruli examined on day seven of disease. These
latter two matrix proteins are known to be specifically induced by
TGF-13 and their presence in the matrix correlates with TGF-p
activity. Suppression of matrix production had a striking thera-
peutic effect on the histological appearance of the nephritic
glomeruli in which the exuberant deposition of matrix was
blocked. The result was that the glomeruli appeared nearly
normal. In these experiments, no toxic effects of decorin admin-
istration were detected.
Decorin gene therapy
Production of a recombinant protein such as decorin is expen-
sive and complex, and this may limit the availability of decorin and
its development as an anti-fibrotic agent. It occurred to us that an
alternative approach is muscle-based gene therapy [35]. This is a
novel form of therapy in which the eDNA of a gene is injected into
the host's skeletal muscle [36, 37]. The muscle cells do not
incorporate the eDNA into their genome, but do utilize it to
synthesize the eDNA's protein product which is then secreted into
the blood stream. It is known that production of the protein
proceeds for several days and then is stopped, and after several
months the eDNA is degraded and disappears from the cells [38].
Gene therapy has several important advantages over therapy
with a recombinant protein. For example, it does not require
repeated intravascular injections for administration, and this may
significantly improve compliance. If the protein is made by the
host it may contain important post-translational modifications and
thus be more "natural" and possibly more effective. Sustained
production and secretion of the protein by muscle cells may lead
to higher tissue concentrations and a greater therapeutic effect
than if administered by intravascular injection. Finally, and im-
portantly, gene therapy is advantageous because it is less expen-
sive and overcomes the need to manufacture and purify a
recombinant protein.
We designed a study to test the therapeutic effect of decorin
gene therapy in the well-established disease model of ATS-
induced glomerulonephritis [39]. As already discussed, this model
resembles human disease and the fibrogenesis has been shown to
be mediated by TGF-13. Our goals in the study were twofold. First,
we wanted to show that decorin gene transfer into skeletal muscle
would result in increased decorin production, and that the decorin
would be delivered by the bloodstream to the kidney. Second, and
this was critical, decorin produced and delivered in this manner
should have a significant therapeutic effect on the disease process.
We used an established gene transfer technique in which cDNA is
injected directly into skeletal muscle. To guarantee optimal gene
expression, we used another established technique of combining
eDNA with a liposome and viral mixture. The decorin expression
vector we employed contained the complete region of rat decorin
cDNA or, as control, the CAT gene.
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Fig. S. Histological changes in glomeruli of
glomerulonephritic rats treated with decorin gene
therapy. Representative PAS stained glomerulus
from a rat on day six of disease treated with
decorin (A) or CAT (B) gene therapy.
Quantification of PAS-positive glomerular
matrix is shown in (C) and individual matrix
proteins accumulated in the glomeruli in (D)
fibronectin EDA, (E) type I collagen and (F)
tenascin. (Reproduced from t391 with
permission).
Following decorin gene transfer, decorin mRNA and decorin
protein were markedly increased in the transfected muscle. Since
decorin is a secreted protein, decorin produced by a highly
vascularized skeletal muscle would be expected to enter the
bloodstream and be delivered to the vascular beds of organs and
tissues. Our results indicate that this happened. For example,
within three days of decorin gene transfer, increased amounts of
immunoreactive decorin were detected in glomeruli, liver and
lung of normal or glomerulonephritic rats. Following gene trans-
fer, the staining pattern of the newly deposited decorin closely
resembles the distribution of decorin that is observed following
intravascular injection of radiolabeled recombinant decorin
[40].
Decorin gene therapy markedly attenuated manifestations of
disease in the glomerulonephritic rats. As shown in Figure 4, the
level of TGF-p mRNA and the number of cells synthesizing
TGF-p protein in nephritic glomeruli were significantly reduced
by decorin gene therapy. The therapeutic benefit of reduction in
TGF-J3 gene expression is clearly revealed in Figure 5. Histolog-
ical sections of glomeruli from nephritic rats treated with CAT
gene transfer showed marked accumulation of pathological ma-
trix. In contrast, glomeruli from nephritic rats treated with decorin
gene transfer showed significantly less matrix accumulation than
disease controls; by day 14, the decorin treated glomeruli were not
significantly different form normal controls.
The molecular basis for the therapeutic effect of decorin gene
therapy on glomerular histology was a substantial reduction in
deposition of the individual components that make up the patho-
logical matrix. Staining for fibronectin EDA, type I collagen and
tenascin was significantly attenuated in nephritic glomeruli from
rats that received decorin gene therapy (Fig. 5). As in our earlier
studies, these matrix proteins were chosen because they are
induced by TGF-13 and, therefore, are sensitive markers of TGF-f3
activity. Proteinuria was also significantly decreased in the decorin
treated rats.
Although this study does not directly identify the mechanism of
decorin's therapeutic action, it is reasonable to assume that it is
because of a reduction in TGF-13 gene expression and the
biological actions of TGF-J3. As described above, decorin binds
TGF-13 via its core protein and there is evidence of a reciprocal
relationship between TGF-f3 and decorin. Taken together, these
data and our results with recombinant decorin and decorin gene
therapy support the idea that decorin acts as an effector molecule
in a feedback ioop that regulates TGF-/3.
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Conclusion
Our work in glomerulonephritis and diabetic nephropathy,
using experimental models and humans, has strongly implicated
overproduction of TGF-f3 as the cause of fibrosis that destroys
renal function in these diseases. Numerous lines of investigation
from other investigators have produced similar evidence. It now
seems clear that in fibrotic disease, repeated tissue injuly or a
defect in TGF-/3 regulation leads to sustained production of
TGF-/3. A central question for future research is to understand
better the cause of TGF-fI dysregulation in fibrotic disease. It is
intriguing to think that aberrant decorin production might be
involved. However, whether decorin production is directly linked
to the pathogenesis of fibrotic disease, our results show that
augmentation of endogenous production of decorin with injection
of recombinant decorin or decorin produced by gene transfer is
therapeutic. Other agents might also be developed as antagonists
of TGF-f3. In our opinion, the results with decorin gene therapy
show the potential of a novel approach to the treatment of human
fibrotic diseases, such as glomerulonephritis and diabetic ne-
phropathy, that are now linked to overproduction of TGF-f3.
Acknowledgments
This work was supported by National Institutes of Diabetes and
Digestive and Kidney Diseases (NIDDK) grants DK 43609 and DK 49374
to W.A.B. and NIDDK grant DK 49342 to N.A.N., and support from the
National Kidney Foundation of Utah.
Reprint requests to Wayne A. Border, M.D., Division of Nephrology,
University of Utah School of Medicine, 50 North Medical Drive, Salt Lake
City, Utah 84132, USA.
References
1. BORDER WA, RUOSLAHTI E: Transforming growth factor-/I in disease:
The dark side of tissue repair. J Clin Invest 90:1—7, 1992
2. BORDER WA, NOBLE NA: Transforming growth factor-/I in tissue
fibrosis. NEnglJ Med 331:1286—1292, 1994
3. SPORN MB, ROBERTS AB: Transforming growth factor-/I: Recent
progress and new challenges. J Cell Biol 119:1017—1921, 1992
4. ROBERTS AB, SPORN MB: Peptide growth factors and their receptors.
in The Handbook of Experimental Pharmacology, edited by SPORN MB,
ROBERTS AB, Heidelberg, Springer-Verlag, 1989, pp 419—472
5. OKUDA S, LANGuINO LR, RUOsLAHTI E, BORDER WA: Elevated
expression of transforming growth factor-/I and proteoglycan produc-
tion in experimental glomerulonephritis. J Clin invest 86:453—462,
1990
6. BAGCHUS WM, HOEDEMAKER PJ, ROZING J, BAKKER WW: Glomer-
ulonephritis induced by monoclonal anti-thy 1.1 antibodies. A sequen-
tial histological and ultrastructural study in the rat. Lab Invest
55:680—687, 1986
7. YAMAMOTO T, WILSON CB: Quantitative and qualitative studies of
antibody-induced mesangial cell damage in the rat. Kidney liii 32:514—
525, 1987
8. ROBERTS AB, SPORN MB: Differential expression of the TGF-/I
isoforms in embryogenesis suggests specific roles in developing and
adult tissues. Mo! Repro Dev 32:91—98, 1992
9. NAKAMURA T, MILLER DE, RUOSLAWrI E, BORDER WA: Production
of extracellular matrix by glomerular epithelial cells is regulated by
transforming growth factor-/I. Kidney mt 41:1213—1221, 1992
10. BORDER WA, OKUDA S, LANGUINO LR, RUOSLAHTI E: Transforming
growth factor-/I regulates production of proteoglycans by mesangial
cells. Kidney mt 37:689—695, 1990
11. Bmcos WH, CORTEZ SL, EL-DAHR SS, SCI-INAPER HW: ECM
degradation by cultured human mesangial cells is mediated by a
PAlplasmin/MMP-2 cascade. Kidney mt 47:1039—1047, 1995
12. TOMO0KA S, BORDER WA, MARSHALL BC, NOBLE NA: Glomerular
matrix accumulation is linked to inhibition of the plasmin protease
system. Kidney mt 42:1462—1469, 1992
13. KAGAMI S, BORDER WA, RUOSLAHTI E, NOBLE NA: Coordinated
expression of /I1 integrins and transforming growth factor-/I-induced
matrix proteins in glomerulonephritis. Lab Invest 69:68—76, 1993
14. TERRELL TG, WORKING PK, Cuow CP, GREEN JD: Pathology of
recombinant human transforming growth factor-/I in rats and rabbits.
mt Rev Exp Pathol 34(Pt B):43—67, 1993
15. ISAKA Y, FUJIWARA Y, UEDA N, KANEDA Y, KAMADA T, 1MM E:
Glomerulosclerosis induced by in vivo transfection of transforming
growth factor-/I or platelet-derived growth factor gene into the rat
kidney. J Clin Invest 92:2597—2601, 1993
16. KovP JB, FACTOR VM, MOZES M, NAGY P, SANDERSON N, BOTFINGER
EP, KLOTMAN PE, THORGEIRSSON SS: Transgenic mice with increased
plasma levels of TGF-/I1 develop progressive renal disease. Lab Invest
74:991—1003, 1996
17. ROBERTS AB, JOYCE ME, BOLANDER ME, SPORN MB: Transforming
growth factor-beta (TGF-/I): A multifunctional effector of both soft
and hard tissue regeneration, in Growth Factors in Health and Disease,
edited by WESTERMARK B, BETSHOLTZ C, HOkfelt, Amsterdam,
Elsevier Science Publishers B.V., 1990, pp 89—101
18. OGAWA Y, KSANDER GA, PR.Arr BM, SAWAMURA Si, ZIMAN JM,
GERHARDT CO, AVIS PD, MURRAY MJ, MCPHERSON JM: Differences
in the biological activities of transforming growth factor-/I and plate-
let-derived growth factor in vivo. Growth Factors 5:57—68, 1991
19. YAMAMOTO T, NOBLE NA, MILLER DE, BORDER WA: Sustained
expression of TGF-/I1 underlies development of progressive kidney
fibrosis. Kidney mt 45:916—927, 1994
20. YAMAMOTO T, NAKAMURA T, NOBLE NA, RUOSLAHTI E, BORDER
WA: Expression of transforming growth factor f3 is elevated in human
and experimental diabetic nephropathy. Proc Nat! Acad Sci USA
90:1814—1818, 1993
21. SHARMA K, ZIYADEH FN: Hyperglycemia and diabetic kidney disease.
The case for transforming growth factor-/I as a key mediator. Diabetes
44:1139—1146, 1995
22. BORDER WA, YAMAMOTO T, NOBLE NA: Transforming growth factor
in diabetic nephropathy. Diabetes Metabol Rev 12:309—339, 1996
23. YAMAMOTO T, NOBLE NA, COHEN AH, NAST CC, HISHIDA A, GOLD
LI, BORDER WA: Expression of transforming growth factor-/I iso-
forms in human glomerular diseases. Kidney mt 49:461—469, 1996
24. SHIHAB FS, YAMAMOTO T, NAST CC, COHEN AH, NOBLE NA, GOLD
LI, BORDER WA: Transforming growth factor-/I and matrix protein
expression in acute and chronic rejection of human renal allografts.
JAm Soc Nephrol 6:2896—294, 1995
25. PETEN EP, STRIKER LI, CAROME MA, ELLIO1-I- SJ, YANG CW,
STRIKER GE: The contribution of increased collagen synthesis to
human glomerulosclerosis: A quantitative analysis of a2(IV) collagen
mRNA expression by competitive polymerase chain reaction. J Exp
Med 176:1571—1576, 1992
26. SHIHAB FS, ANDOH TF, TANNER AM, NOBLE NA, BORDER WA,
FRANCESCHINI N, BENNETF WM: Role of transforming growth fac-
tor-/Il in experimental chronic cyclosporine nephropathy. Kidney mt
49:1141—1151, 1996
27. BORDER WA, OKUDA S, LANGuINO LR, SPORN MB, RU05LMITI E:
Suppression of experimental glomerulonephritis by anti serum against
transforming growth factor /I1. Nature 346:371—374, 1990
28. SHAH M, FOREMAN DM, FERGUSON WJ: Control of scarring in adult
wounds by neutralizing antibody to transforming growth factor /I.
Lancet 339:213—214, 1992
29. RUOSLAHTI E, YAMAGUCHI Y: Proteoglycans as modulators of growth
factor activities. Cell 64:867—869, 1991
30. HILDEBRAND A, ROMARIS M, RASMUSSEN LM, HEINEGARD D,
TWARDZIK DR, BORDER WA, RUOSLAHTI E: Interaction of the small
interstitial proteoglycans biglycan, decorin and fibromodulin with
transforming growth factor /I. Biochem J 302:527—534, 1994
31. KAHARIS V-M, LARJAVA HK, UITrO I: Differential regulation of
extracellular matrix proteoglycan (PG) gene expression. J Biol Chem
266:10608—10615, 1991
32. BREES DK, IKEGAYA N, KETrELER M, NOBLE NA, BORDER WA:
Deficiency of the TGF-/I antagonist, decorin, precedes matrix depo-
sition in experimental glomerulonephritis. (abstract) JAm Soc Neph-
rol 5:801, 1994
1396 Border and Noble: TGF-13 and glomemlar injuty
33. WESTERGREN-THORSSON G, HERNNAS J, SARNSTRAND B, OLDBERG A,
HEINEGARD D, MALMSTROM A: Altered expression of small proteo-
glycans, collagen, and transforming growth factor-fl, in developing
bleomycin-induced pulmonary fibrosis in rats. J C/in Invest 92:632—
637, 1993
34. BORDER WA, NOBLE NA, YAMAMOTO T, HARPER J, YAMAGUCHI Y,
PIERSCHBACHER MD, RUOSLAHTI E: Natural inhibitor of transforming
growth factor-13 protects against scarring in experimental kidney
disease. Nature 360:361—364, 1992
35. WOLFF JA, MALONE RW, WILLIAMS P, CHONG W, ACSADI G, JA.r'u A,
FELGNER PL: Direct gene transfer into mouse muscle in vivo. Science
247:1465—1468, 1990
36. BLAU HM, SPRiNGER ML: Gene therapy—A novel form of drug
delivery. N Engi J Med 333:1465—1468, 1995
37. BLAU HM, SPRINGER ML: Muscle-mediated gene therapy. N Engi
J Med 333:1204—11207, 1995.
38. DANKO I, WOLFF JA: Direct gene transfer into muscle. Vaccine
12:1499—1502, 1994
39. Isic Y, BREES DK, IKEGAYA K, KANEDA Y, IMAI E, NOBLE NA,
BORDER WA: Gene therapy by skeletal muscle expression of
decorin prevents fibrotic disease in rat kidney, Nature Med 2:418—
423, 1996
40. NOBLE NA, HARPER JR, BORDER WA: In vivo interactions of
TGF-13 and extracellular matrix. Progr Growth Factor Res 4:369—
382, 1992
